Aandelen in “Biotechnologie”

Aandeel Datum Koers Evolutie
vlag Fate Therapeutics Inc 15/12 1,120 USD
-2,61% 		-2,61%
vlag Fennec Pharmaceuticals Inc 12/12 7,550 USD
+0,80% 		+0,80%
vlag FibroGen Inc 15/12 10,040 USD
+19,81% 		+19,81%
vlag Foghorn Therapeutics Inc 12/12 4,440 USD
-0,89% 		-0,89%
vlag Formycon AG 15/12 23,550 EUR
-1,05% 		-1,05%
vlag Forte Biosciences Inc 12/12 21,370 USD
-5,65% 		-5,65%
vlag Fortress Biotech Inc 15/12 3,320 USD
+13,31% 		+13,31%
vlag Fortress Biotech Inc 12/12 7,708 USD
+0,10% 		+0,10%

Nieuws over “Biotechnologie”

00:00 · Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 · Persbericht

00:00 · Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 · Persbericht

15/12 · Cellectis Announces Arbitral Decision in Dispute with Servier · Persbericht

15/12 · Kodiak Sciences Announces Proposed Public Offering of Common Stock · Persbericht

15/12 · Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic · Persbericht

15/12 · Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins · Persbericht

15/12 · Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis · Persbericht

15/12 · Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis · Persbericht

15/12 · RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells · Persbericht

15/12 · NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris · Persbericht

14/12 · /C O R R E C T I O N -- MyOme, Inc/ · Persbericht

12/12 · Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance · Persbericht

12/12 · FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS · Persbericht

12/12 · Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants · Persbericht

11/12 · Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference · Persbericht

11/12 · Platform Technologies Drive $211B Surge in Precision Cancer Treatment · Persbericht

11/12 · Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually · Persbericht

11/12 · Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology · Persbericht

11/12 · IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma · Persbericht

11/12 · Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co. · Persbericht

10/12 · QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm · Persbericht

Mijn selecties